Scott Jordan Email & Phone Number

Chicago, Il, Us

Atlanta, Georgia, Us

Joined Biotech Exec's IGNITE Network, a specially selected network of talent; seasoned professionals that are readily available for placement or advice.

Raising Spirits Holding Company launched in 2022 with the mission to produce quality spirits, be accountable, and utilize the business to form healthy relationships with people and the environment. The Founders of Raising Spirits seek to leverage the tremendous market advantages of Central America (limited market competition in the craft distillery market, lower labor / operating costs, abundant produce ideal for spirits production) and a growing tourist industry to pioneer new craft distilleries within the untapped region. Raising Spirits and it’s craft vodka subsidiary (Destilería La Zona) chose Honduras and the island of Roatán as the company’s first market given proximity to the company’s manufacturing / distribution facilities in Comayagua, the historical Capital of Honduras, and growing consumer base. Over 1 million tourists visit Roatán each year (Source: Roatán Tourist Bureau) via air and cruise ships to experience the island’s beautiful landscape and world class diving. The company employs a unique scaling strategy of partnering with merchants along cruise ship ports of call and prioritizes giving back to local communities via a 501(c)(3), Abundant Life Foundation, which supports housing developments in Central America.

Early-stage biotechnology company dedicated to developing and commercializing a novel gene therapy founded at Northwestern University to improve the treatment of atrial fibrillation (AF) by targeting the underlying cause of the disease. Formulate the vision, strategy, and business plan for closing strategic partnerships with major medical device / biopharmaceutical companies. Lead and execute business development initiatives including outreach and negotiation of deal terms with potential partners. Prepare, evaluate and present robust financial models to internal (Board) and external constituents supporting the company's financing goals.

Inglewood, Ca, Us

Assisting the ImaginAb Board / management team execute M&A and capital raising strategic initiatives including the sale of a novel radiotherapy imaging agent (89Zr crefmirlimab berdoxam - CD8 ImmunoPET) in conjuction with Jefferies and financing the company's radiopharmaceutical therapies (RPT) including IAB56 (Integrin αvβ6 for Solid Tumors) and IAB57 (DLL3 in Small-Cell Lung Cancer).

Singapore, Singapore, Sg

Responsible for capital raising including leading interactions with bankers and analysts, collaborating with drug development partners (Merck / Roche) on the company’s MNK 1/2 inhibitor clinical programs, and establishing discovery, development, and partnership agreements with major pharma. Expanding AUM’s drug pipeline via research and collaborations at major universities and co-development / in-licensing partnerships with companies seeking AUM's global development and optimization capabilities.

Houston, Texas, Us

Provided leadership in the evaluation, development, implementation, and management of partnerships, collaborations, and acquisitions. Led a team of functional experts in science, clinical, program management, global marketing, legal and finance to evaluate opportunities, develop relationships with external parties, and ensured the corporate business development strategies were implemented.Stingray is developing a potent and selective small molecule inhibitor of ENPP1. IND filed in the 1Q2023 and Phase 1 studies are ongoing. ENPP1 is the direct negative regulator of the STING pathway which is essential innate immune response. Received $13M CPRIT award in 2023.

Houston, Texas, Us

Worked closely with senior management / Board of Directors formulating corporate strategy including enhancing shareholder value through M&A, capital raising, and business development / partnerships. Generated and reviewed statistical information across business units leading to informed decision making and improved performance including the identification of new opportunities for further business growth.

Houston, Texas, Us

CFO of promising biotechnology companies located within JLABS/ Texas Medical Center (TMC); Salarius Pharmaceuticals (epigenetics - LSD1 Inhibitor) and Iterion Therapeutics (cancer stem cells - Wnt/Beta Catenin). Worked closely with the Cancer Prevention and Research Institute of Texas (CPRIT) who awarded Salarius $18.7M of non-dilutive funding in 2016 to develop the company's lead small molecule, Seclidemstat, through Phase 1 clinical studies. Iterion received a $16.1M CPRIT award in 2015 and entered Phase 1 in 2018. Managed CPRIT directives, performed traditional CFO responsibilities, and supervised corporate finance, investment banking, and business development / licensing activities.CPRIT: Contracts, budget submissions, invoice/receipt, and audit proceduresTraditional CFO Roles: Controller (bookkeeping, banking relationships, tax, budgeting, auditing), accounting and financial reporting / planning (working capital optimization, cash flow forecasts, quarterly / annual financial plans), and administrative management (facilities, procurement)Corporate Finance / Investment Banking: Prepared management presentations and financial documents (valuation models, subscription booklets, cap tables, waterfalls), identified and communicated with investors, negotiated term sheets, and evaluated / implemented “exit” strategies including M&A, reverse merger, and IPOBusiness Development: Secured Ex-US licensing agreements with HLB Biosciences for portfolio company assets: Salarius' Seclidemstat (Ewing sarcoma, late-stage hormonal cancers) and Iterion's Tegavivint (Desmoid tumors, AML, non-small cell lung cancer).

Northbrook, Il, Us

Co-Founder / Adviser to online investment marketplaces (HealthiosXchange, CapBridge) and performed investment banking services in partnership with Healthios, a boutique healthcare investment bank with offices in Chicago and Bangkok assisting companies syndicate capital from venture capitalists and limited partners on a direct basis. In June of 2015, Healthios Xchange partnered with the Singapore Exchange (SGX) and Clearbridge Accelerator (CBA) launching CapBridge, http://www.capbridge.sg the global private capital exchange connecting institutional investors to professionally led, syndicated transactions in emerging growth companies. SGX raises pre-IPO private rounds through its co-investment platform partner, CapBridge, and further capital / liquidity on SGX via IPOs. Liquidia Technologies secured pre-IPO round via CapBridge platform in 2017 and subsequently filed an IPO on Nasdaq in July of 2018 raising $57.5M.S. Jordan Associates www.sjordanassociates.com and Healthios introduced HealthiosXchange (H/X), the premier investment marketplace serving the healthcare industry to the global financial markets, in August of 2013. H/X connected institutional and accredited investors with emerging growth companies inspiring new investment and financing alternatives in a dynamic, real-time and transparent transaction environment. Over 1,500 healthcare companies and 3,500 investors joined and participated on H/X.Crowd Finance Portal - Online platform for early-stage, non venture-backed healthcare companies to raise capital from Accredited investors via Special Purpose Vehicles (SPV's) enabling investors to diversify investments across a broad range of companies/therapeutic sectors (lower investment minimums)Ex.PR.E.S.S (Exclusive Preferred Sponsored Securities) Portal - “Carry Free” co-investments alongside top-tier institutional investors and the most important strategic buyers

Assisted Healthios with corporate finance (private placements), business development (licensing, deal structuring), and strategic advisory (buy and sell-side M&A) engagements. Led client interactions, drafted core documents (executive summaries, management presentations, private placement memorandums, prospectus), prepared financial models (discounted cash flow, merger and acquisition accretion/dilution analysis), managed corporate events (~JPMorgan Healthcare Conference, ASCO, AACR), and published research https://www.linkedin.com/today/author/sjordan1 Supervised corporate finance initiatives for IRX Therapeutics leading to collaboration with a leading pharmaceutical company, and Corium International completing an initial public offering (IPO)In 2012, assisted Healthios with raising over $50 million of capital for biopharm companies including Cardiosolutions, Liquidia Technologies, and Pinnacle BiologicsRaised over $15 million of capital for Calibra Medical, maker of the FINESSE Patch Pen for Type 1 and 2 diabetes, leading to the company’s acquisition by Johnson & Johnson

Chicago, Illinois, Us

TD2 is a leading oncology translational research organization / CRO specializing in precision medicine/genomics. Services provided to biopharmaceutical companies include lead optimization through IND/clinical (predictive animal models - proof of concept/mechanism of action), implementation of the DE-RISK platform (innovative clinical design), and strategies for rapid regulatory approval. Represented TD2 and clients at major industry conferences (BIO/ASCO).

Us

Business development activities included structuring licenses, distribution agreements, technology acquisitions, and research agreements with large pharmaceutical organizations, universities and government agencies. Managed multidisciplinary teams conducting technical evaluation and financial valuation as well as crafting structures for both strategic partnerships and co-promotion development deals. Responsible for out-licensing worldwide and/or regional rights to LE-SN38 (topo-1 inhibitor), LErafAON (antisense), and IL13-PE38. Established strong relationships with Far-East biopharma companies resulting in a collaboration with Nippon Kayaku for the rights to IL13-PE38 in Japan. Identified opportunities for out-licensing NeoPharm’s proprietary liposome drug delivery technology, NeoLipidTM. Prepared and executed drug delivery presentations including establishing the initial contact, negotiation of contract terms, and building leadership consensus leading to the signing of feasibility studies and development deals. Signed licensing distribution agreements with Nippon Genetics and Avanti Polar Lipids from 2003-04.Developed a growing and productive network of contacts and deal experts with senior executives, venture capitalists, and investment bankers. Assisted NeoPharm CEO with secondary offering of 4.3 million shares at $18.25 per share underwritten by UBS Warburg and priced on 1/21/04 (raised $74 million in net proceeds).

Lake Forest, Il, Us

Supervised the sales and marketing activities of 11 Representatives covering 14 states for Akorn Ophthalmics, a manufacturer and distributor of ophthalmic pharmaceuticals/generics and diagnostics. Managed an annual budget of over $50 million. Specialized in developing and executing business strategies for increasing profitability including market and competitive analysis, forecasting, product positioning, and pricing.

Abbott Park, Illinois, Us

Proficiency in marketing diagnostic laboratory systems, reagents, and service contracts within Abbott’s Diagnostic Division (ADD) division to physician group practices (Urology, Cardiology, Hematology, OBgyn), management service organizations, integrated service networks, and group purchasing organizations (GPOs). Clients included The University of Chicago, Advocate, and MedPartners.

Mba, Finance

Bachelor'S Degree, Marketing

College Prep